معرفی
Professor Nathan Palpant is a Group Leader at the Institute for Molecular Bioscience, University of Queensland, with affiliations to the School of Biomedical Sciences and the Centre for Cardiovascular Health and Research. His research focuses on cardiovascular development, stem cell biology, and genomics, with a particular emphasis on translating discoveries into therapeutics for heart disease. He holds a PhD from the University of Michigan and completed postdoctoral training at the University of Washington.
His research interests include developing drugs to prevent ischemic heart injury (e.g., Hi1a from funnel-web spider venom), advancing genomic tools like TRIAGE for variant analysis, and understanding stem cell differentiation mechanisms. He has received multiple awards, including the National Heart Foundation Future Leader Fellowship and the Lorne Genome Millennium Science Award.
Key projects involve venom-derived therapeutics, epigenetic regulatory analysis, and functional genomics platforms. His team collaborates with industry partners such as Infensa Bioscience, HAYA Therapeutics, and Merck. Current grants include studies on glycemic variability in diabetes, genomic variant classification, and clinical trials for heart protection (HEART REHAB).
Professor Palpant supervises PhD students in areas like stem cell differentiation, genomic analysis, and venom pharmacology. His lab integrates wet-lab techniques with computational methods, contributing to over 90 publications and forming the basis for biotech ventures like Sana Biotechnology and Infensa Bioscience.
